Yamana Gold Inc. (NYSE:AUY) last session’s volume of 4.77 million shares was lower than its average volume of 9.12 million shares. The stock hit $2.64 through the close by scoring -1.12%.Yamana Gold Inc. (AUY) Analyst Opinion
Yamana Gold Inc. has a consensus hold rating from 16 Wall Street analysts, and the number of shares currently sold short amount to at least 1.8% of shares outstanding. The stock sank -8.33% last month and is down -6.05 this year. Wall Street is only getting more bullish on the stock, with 6 of analysts who cover AUY having a buy-equivalent rating. Analysts have placed a $3.61 price target on Yamana Gold Inc., suggesting a 36.74% gain from recent close. It’s currently trading about -33.16% below its 52-week high.Yamana Gold Inc. Earnings Surprise
Yamana Gold Inc. (AUY) failed to surprise the stock market in its last reported earnings when it earned 0 a piece versus the consensus-estimated $0.01. Its revenue totaled $429.24 million up 6.38% from the previous quarter.Yamana Gold Inc. (NYSE:AUY) Intraday View
This stock (AUY) is ahead of its 52-week low with 19.46%. Its last month’s stock price volatility remained 2.77% which for the week stands at 3.21%. The share price has moved backward from its 20 days moving average, trading at a distance of -3.26% and stays -3.74% away from its 50 days moving average. Over the last five days, shares have faced -0.38% losses and now is down -5.25% since hitting its 200-day moving average of $2.68. Yamana Gold Inc. (AUY) has made its way to a 12-month decline of -29.6%.
Turning to CytomX Therapeutics, Inc. (NASDAQ:CTMX), its shares were trading at $21.75 a gain of $0.21, on the trading floor. The stock, after opening at $21.75, touched a high of $22.31 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. CytomX Therapeutics, Inc. has 3 buy ratings, 1 holds and 0 sells even after the stock tumbled -11.84% from its high of $24.67 to a $839.33 million market value through last close.CytomX Therapeutics, Inc. (CTMX) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.67 to 1.67 during a month. Analysts set a 12-month price target of $35 a share. The target implies a 60.92% spike from where the shares are currently trading. Also, the current price highlights a discount of 47.13% to analysts’ high consensus price target.CytomX Therapeutics, Inc. (NASDAQ:CTMX) Intraday Trading
The counter witnessed a trading volume of 0.32 million shares versus an average volume of 0.32 million shares during last trading session. Its last month’s stock price volatility remained 6.75% which for the week approaches 5.09%. The lowest price the stock reached in the last trading day was $21.5 and compares with the $9.85 52-week low. The stock recovered 120.81% since its low point and has performed 97.91% year-to-date.